Northland Capital partners view on Evgen Pharma PLC LON:EVG: First Patient Dosing in this trial represents another major milestone for Evgen. With two Phase 2 trials now dosing patients and with both trials fully funded, the group is well positioned to deliver significant value creation in the near future—both trials are expected to report top line results in calendar H1-2018. As such, we reiterate that the Company’s shares are significantly undervalued.
|First patient dosed in breast cancer trial|
|n Evgen announced that the first patient has been dosed in the Company’s Phase II clinical trial of SFX-01 in breast cancer.
n The trial is being led by Manchester’s Christie NHS Foundation Trust, Europe’s largest single-site cancer centre, and will include approximately 15 sites in 5 countries.
n The first patient was dosed on 16 January 2017 at the Cliniques universitaires Saint-Luc, the largest hospital in Brussels, Belgium.
n The trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients whose cancer cells are estrogen-receptor positive (ER+).
n Evgen also announced the appointment of a new CFO and Head of Clinical Operations.
Source: Northland Capital Partners Limited. *Northland Capital Partners acts as Nomad and Broker